Deoxycytidine Kinase (DCK) Antibody – Rabbit Polyclonal

Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity. [provided by RefSeq, Jul 2008]

Function: Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents. Ref.19 Ref.22

Catalytic activity: NTP + deoxycytidine = NDP + dCMP. Ref.16 Ref.19 Ref.20 Ref.22

Subunit structure: Homodimer. Ref.16 Ref.17

Subcellular location: Nucleus Ref.8.

Post-translational modification: Phosphorylated and activated in vitro upon phosphorylation at Ser-74 by CSNK1D/CK1. Ref.13

Sequence similarities: Belongs to the DCK/DGK family.

Caution: Was shown to be phosphorylated and activated by CSNK1D/CK1 in vitro but probably not in vivo (Ref.13).

Biophysicochemical propertiesKinetic parameters:KM=6.2 µM for deoxycytidine (dC) Ref.16KM=15.5 µM for cytarabine (araC)KM=22 µM for gemcitabine (dC)